Look for Eli Lilly's Verzenio to hit $4.6B, thanks to early breast cancer win: analyst

Look for Eli Lilly's Verzenio to hit $4.6B, thanks to early breast cancer win: analyst

Source: 
Fierce Pharma
snippet: 

In the kinase inhibitor class of breast cancer drugs, Pfizer’s Ibrance has held a strong lead in market share—and sales—over Eli Lilly’s Verzenio.

But on the heels of Verzenio's strong showing in HR+/HER2- early breast cancer—and Ibrance's miss—one influential analyst figures the Lilly drug will quickly pick up steam. The upshot? About $4.6 billion in sales at peak, significantly more than most pharma watchers now expect from the med.